MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, comprising medicines, vitamins, medical devices, and test kits; and offers consumer goods, such as home and personal care products, including toiletries, baby care products, soaps and detergents, and sanitizers. The company also provides wholesale cash and carry; diagnostic, pathological, and laboratory testing services, as well as engages in the contract manufacturing of private label pharmaceuticals. It operates stores in Telangana, Andhra Pradesh, Karnataka, Tamil Nadu, West Bengal, Maharashtra, Orissa, Madhya Pradesh, Chhattisgarh, Kerala, and Puducherry, as well as online platform. The company was incorporated in 2006 and is based in Hyderabad, India.
Revenue projections:
Revenue projections for MEDPLUS MEDPLUS's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.
Financial Ratios:
currentRatio
0.000000
forwardPE
38.595173
debtToEquity
64.360000
earningsGrowth
1.942000
revenueGrowth
0.036000
grossMargins
0.253480
operatingMargins
0.042210
trailingEps
14.820000
forwardEps
15.120000
With a forward EPS greater than its trailing EPS, MEDPLUS is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.
Price projections:
Price projections for MEDPLUS Price projections for MEDPLUS have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for MEDPLUS's growth and market performance.
Recommendation changes over time:
Recommendations trend for MEDPLUS
MEDPLUS has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as MEDPLUS is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
An in-depth look at the UK’s Q2 2025 GDP release by ONS,...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.